Skip to main content
Premium Trial:

Request an Annual Quote

Combimatrix Reports a Jump in Q3 Revenues; R&D Flat

NEW YORK, Oct. 21 (GenomeWeb News) - CombiMatrix reported third-quarter 2004 revenues of $753,000, up from $181,000 in the third quarter of 2003, the company's parent, Acacia Research, reported today.

 

Revenues for the quarter included $685,000 in "government contract revenues" and $68,000 in "microarray product sales and other contract service revenues," said the company.

 

Research and development expenses were flat at $1.7 million for the period year over year. These expenses included increased government contract costs incurred in connection with the company's commitments under its Department of Defense biowarfare detection contract, and other interenal R&D efforts, the company said.

 

Net loss narrowed by 22.8 percent, to $3.5 million during the third quarter of 2004 from $4.5 million during the comparable period in 2003, the company added.

 

CombiMatrix had around $26.7 million in cash, equivalents, and short-term investments as of Sept. 30.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.